Background and Aims: The polyunsaturated fatty acids (PUFA) arachidonic acid (AA, n-6) and eicosapentaenoic acid (EPA, n-3) are precursors of eicosanoids and other lipid mediators which have critical roles in inflammation. The mediators formed from the different PUFA have different potencies. We hypothesised that metabolic changes associated with colonic mucosal inflammation would modify the bioavailability of the eicosanoid precursors AA and EPA. Methods: Colonic mucosa biopsies were obtained from patients with ulcerative colitis and from matched controls. Inflammation was graded endoscopically and histologically. Esterified and Abbreviations: PUFA, polyunsaturated fatty acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; UC, ulcerative colitis; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; α-LNA, alpha linolenic acid; PG, prostaglandins; LT, leukotrienes; 5-ASA, 5-aminosalicylic acid; HPLC, high performance liquid chromatography; SPE, solid phase extraction; LC/MS, liquid chromatography mass spectrometry; EI-SIM, electron impact selective ion monitoring; PPARγ, peroxisome proliferator activator receptor γ; GC/MS, gas chromatography mass spectrometry; FA, fatty acid. A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
Ulcerative colitis (UC) is a chronic, relapsing intestinal inflammatory disorder of the colonic mucosa, with variable distribution but limited to the distal bowel (distal colitis and proctitis) in 60% of cases. 1 The aetiology of UC is unconfirmed but involves an inappropriate immunological response 2 characterised by a progressive neutrophilic infiltration which correlates to disease activity. 3 However, the specific trigger which initiates and propagates the inflammatory response in non-inflamed and quiescent mucosa is unknown.
Eicosanoids, including prostaglandins (PG) and leukotrienes (LT), are inflammatory mediators which are rapidly formed and degraded in-situ and with pleiotropic functions including promotion of neutrophil chemotaxis. 4, 5 Mucosal inflammation in UC is characterised by an elevation in concentrations of eicosanoids formed from the n-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA), including both PGE 2 6 and LTB 4 .
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UC responds to therapeutic interventions that target eicosanoid production such as 5-aminosalicylate acid (5-ASA). 8, 9 Eicosanoids are also derived from the n-3 PUFA eicosapentaenoic acid (EPA) and the mediators produced from AA and EPA differ in their inflammatory potency. 10, 11 Furthermore, inflammation resolving mediators termed resolvins are produced from EPA and another n-3 PUFA docosahexaenoic acid (DHA). 12 Thus, the inflammatory state may be, in part, determined by the amounts of the various precursors for lipid mediators (i.e. AA, EPA and DHA). The non-esterified fatty acid precursors for lipid mediator synthesis are released from phospholipids, into which they are esterified, by phospholipase A 2 that is up-regulated during inflammatory conditions. 13 In turn, these fatty acids may be synthesised from less structurally complex precursors (AA from linoleic acid (LA) and EPA and DHA from α-linolenic acid (α-LNA)) via a common metabolic pathway in which the two families of fatty acids compete with one another. [13] [14] [15] [16] Competition between these families may lead to a failure to synthesise EPA and DHA; a situation which in theory favours ongoing inflammation.
It is not clear whether diet, leukocyte infiltration or local metabolic induction of PUFA synthetic pathways plays a role in induction, propagation or resolution of inflammation in general or in UC in particular, via alteration of eicosanoid production.
We hypothesised that local metabolic induction associated with colonic mucosal inflammation would modify the bioavailability of the eicosanoid precursors AA and EPA. In order to gain a deeper understanding of PUFA availability in UC we have measured the esterified and non-esterified bioactive PUFA in gut mucosal biopsies from patients with quiescent and active UC and from matched healthy controls.
Subjects, Materials & Methods

Subjects and Mucosal Biopsy
This was a prospective case-controlled study of UC patients and age and sex-matched healthy controls. Patients were identified during attendance at gastroenterology outpatients' clinics at the Royal Haslar and St Mary's Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK between November 2008 and July 2009. The diagnosis of UC was based on endoscopic and histological investigation. 17, 18 All recruited patients underwent a questionnaire based assessment of their demographic characteristics, previous and presenting medical history, UC history and dietary history. Clinical disease activity was determined using the UCDAI score. 19 Patients with clinical symptoms of active disease underwent unprepared flexible sigmoidoscopy examination as part of their routine clinical management. An endoscopy assessment was undertaken by two endoscopists blinded to the patient's clinical presentation using a validated scoring tool 18 to stratify patients into active or quiescent UC, or normal mucosa and with photographic evidence obtained. Biopsies were taken according to a standard protocol, specifically developed to measure target analytes in adjacent areas of non-inflamed and inflamed mucosa in patients with active distal UC. Flexible sigmoidoscopy in patients with active distal UC to above visual demarcation of normal mucosa was followed by grab biopsy, obtained using flexible biopsy forceps, in endoscopically normal and inflamed areas.
A control group of age and sex matched patients undergoing unprepared flexible sigmoidoscopy for other clinical indications but without presenting or previous medical history suggestive of UC were recruited, and with subsequent confirmation of histologically normal colonic mucosa entered into the study as control subjects. Random biopsies were taken and stored as described above.
Mucosal biopsy samples were immediately snap frozen in sealed cryovials at the time of mucosal biopsy, and stored in liquid nitrogen until use, consistent with known long term lipid stability at/below − 80°C. 20 Exclusion criteria were age less than 16 or greater than 80 years; refusal to undergo endoscopic evaluation; diagnosis of colitis of alternative aetiology; concurrent use of non-steroidal anti-inflammatory medication; and inability to provide consent.
Food Frequency Questionnaire
A validated semi-quantitative food frequency questionnaire 21 was administered to estimate intake of individual fatty acids including PUFA over the preceding 4 weeks. Completed questionnaires were analysed by Tinuviel software (Warrington, UK). Data is presented as mean ± SEM as g/day.
Histological Analysis
Histological assessment of biopsy samples was performed by a histopathologist blinded to patients' identities including clinical data. Biopsy material was paraffin embedded and subjected to serial haematoxylin and eosin staining and scoring according to a validated histological scoring system (Gomes score -0 = normal, 1 = mild oedema and inflammation in lamina propria; 2 = crypt abscess formation and inflammation in lamina propria; 3 = more severe inflammation with destructive crypt abscesses +/− granulomata; 4 = more severe inflammation with active ulceration) to grade severity of histological inflammation. 
Liquid-liquid Extraction and Formation of Fatty Acid Methyl Esters 20
Biopsy samples were thawed and a deuterated methanolic 1 N KOH extract was formed in situ by addition to the biopsy of 140 μL 10 N KOH and 1250 μL MeOD/deuterated-internal standard cocktail on ice. Samples were then agitated for 90 min at 55°C, followed by cooling on ice, addition of 116 μL 24 N H 2 SO 4 , with agitation, incubation and cooling steps repeated. Following addition of 200 μL heptane, vortex mixing and centrifugation, the organic phase was transferred to chromatography vials and stored at − 20°C until analysis within 48 h.
GC/MS Analysis
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UV protected samples were analysed using hyphenated gas chromatography on an Agilent 6890N gas chromatograph (Agilent, Santa Clara, CA, USA), installed with an autosampler and a 100 m × 0. 25 HPLC-grade glacial acetic acid and methyl formate were obtained from Sigma-Aldrich (Gillingham, UK). Solid-phase extraction (SPE) cartridges (C 18 -E, 500 mg, 6 ml) were obtained from Phenomenex (Macclesfield, UK). De-ionised water was prepared using Barnstead Nanopure from Triple Red Laboratory technology (Long Crenden, UK).
Solid Phase Extraction
Extraction of fatty acids was carried out as described previously 23 .
LC/MS Analysis
LC/MS analysis was performed using Accela UHPLC system (Thermo Scientific, Hemel Hempstead, U.K.) coupled to LTQ Velos (Thermo, Hemel Hempstead, UK) linear ion trap (LIT)-orbitrap, according to a previously described method. 23 MS spectra, along with retention times and isotope distribution patterns from the MS spectra, were used to identify fatty acids. Data was presented semi-quantitatively as area percentage (area %).
Statistical Analysis
Fatty acid data are expressed as % of total PUFA. SPSS 18 (SPSS Inc., Chicago, IL) was used for data input and analysis. Normality tests (Shapiro-Wilk) revealed non-parametric data. Values and ratios within inflamed compared with noninflamed mucosa are quoted as median and inter-quartile range. The primary outcome variables were analysed using Wilcoxon signed rank pair analysis and Mann-Whitney U test for non-parametric variables, and one-sample Wilcoxon signed rank analysis for ratios. Correlations were tested using Spearman's rank correlation. Subgroup analysis to investigate the effect of no 5-ASA or corticosteroids (n 18) intervention was undertaken.
Ethical Considerations
The study was approved by the Isle of Wight, Portsmouth and South East Hampshire research ethics committee (project number 08/H0501/82). All subjects provided written informed consent.
Results
Subjects
Patients with active UC (n 69), quiescent UC (n 16) and age and sex matched control subjects (n 69) were recruited. Biopsy data sets of 'paired' macroscopically inflamed and non-inflamed tissues were available in 54 patients with active UC. Baseline characteristics of patients and controls are shown in Table 1A . There were no significant differences in demographic or disease characteristics in UC patients in the paired compared to non-paired groups. Control subjects presented with IBS (n 32), rectal polyps (n 4), haemorrhoids (n 4), diverticular disease (n 5), other non-inflammatory presentations (n 5), and normal findings (n 15).
Consistency of Endoscopic and Histological Evaluation
Biopsy specimens (n = 54) within endoscopically determined non-inflamed mucosa were scored histologically. Normal histology was described (n = 38) in 74%. Microscopic inflammation was evident (n = 14) in 26%, of which mild oedema and inflammation in lamina propria (n = 13) were the predominant histological appearance.
Dietary Analysis
Dietary intake (including PUFA) was evaluated in active UC (n 53), quiescent UC (n 16) and controls (n 53). Patients with active UC had lower daily intake of the two essential fatty acids LA (4.9 g ± 1.3 g/day vs. 8.2 g ± 1.5 g/day) and α-LNA (0.56 g ± 0.15 g/day vs. 0.94 g ± 0.18 g/day) (both p b 0.050). There were no significant differences in intake of AA, EPA, DPA or DHA between patients and controls. In addition, there were no significant differences in intake of LA, α-LNA, AA, EPA, DPA or DHA in patients with quiescent UC compared with controls.
Esterified Fatty Acid Pool
Comparison of fatty acids within the esterified lipid pool in inflamed and non-inflamed mucosa from UC patients is shown in Table 2 . AA, DPA and DHA were significantly higher (all p b 0.001) and LA, α-LNA and EPA were significantly lower (all p b 0.001) in inflamed compared with non-inflamed mucosa. The ratio of FA in inflamed compared with noninflamed mucosa demonstrates increased availability of AA, DPA and DHA (all p b 0.001) and decreased availability of LA, α-LNA and EPA (all p b 0.001).
Comparison of fatty acids within the esterified lipid pool in inflamed mucosa from UC patients and from age-sex matched controls is shown (Table 3) . AA, DPA and DHA were significantly higher (all p b 0.001) and LA, α-LNA and EPA were significantly lower (all p b 0.001) in inflamed mucosa of patients with UC compared with mucosa of control subjects.
Comparison of fatty acids within the esterified lipid pool in non-inflamed mucosa from UC patients with age-sex matched controls did not show significant differences other than for DPA which was significantly lower in non-inflamed mucosa (Table 3) .
Correlations of Mucosal Esterified Lipid FA With Endoscopic Disease Activity
The mass % of each individual esterified fatty acid within mucosa in colitis patients was correlated against endoscopic inflammatory score (Fig. 1) 
Non-esterified Fatty Acid Pool
Comparison of non-esterified fatty acids in inflamed and non-inflamed mucosa from UC patients is shown (Table 4) (Table 1B) .
Analysis of mucosal esterified FA demonstrated that AA, DPA and DHA were significantly higher (all p b 0.001) and LA, α-LNA and EPA were significantly lower (all p ≤ 0.001) in inflamed compared with non-inflamed mucosa.
Comparison of non-esterified fatty acids within the same group demonstrated that AA (p b 0.005) and DPA (p b 0.001) were significantly higher and α-LNA (p b 0.050) and EPA (p b 0.010) significantly lower in inflamed compared with non-inflamed mucosa.
Ratios of n-3 and n-6 PUFA and Association With Disease Activity
Comparison of ratios of AA/LA, EPA/α-LNA and AA/EPA (all p b 0.001) in esterified fatty acids between inflamed and non-inflamed and inflamed and control mucosa demonstrated higher values in inflamed mucosa (Table 5 ). These findings were repeated in non-esterified fatty acids for AA/LA and AA/EPA (all p b 0.001), whereas EPA/α-LNA (p = 0.702) was not significantly different (Table 5 ). Ratios in non-inflamed mucosa and control mucosa were not significantly different.
Mucosal PUFA Composition in Quiescent Disease
Analysis of mucosal PUFA composition in 16 patients (age 46.9 years; male n 8 [50%], female n 8 [50%]) with quiescent disease compared with controls (n 69) was carried out. AA was significantly higher (p b 0.01) and LA was significantly lower (p b 0.05) than control mucosa (Table 3) . No significant differences were seen in the other measured FA; however, there was a non-significant trend noted towards lower α-LNA in quiescent mucosa. 
Discussion
In the current study we demonstrate differences in esterified and non-esterified PUFA between inflamed and noninflamed parts of the colonic mucosa in patients with UC and between the inflamed colonic mucosa of patients with UC and that of controls. There were no differences between non-inflamed colonic mucosa of UC patients and that of controls. However, there were differences in quiescent mucosa compared with control mucosa. The findings suggest that inflammation of the colonic mucosa in UC is associated with marked and contrasting changes in n-3 and n-6 PUFA availability. Specifically this includes a marked increase in availability of the n-6 fatty acid AA, the metabolic substrate for the generation of 2-series prostaglandin and 4-series leukotriene families of eicosanoid mediators. Conversely there was a decrease in the availability of the n-3 fatty acid EPA, the substrate for the production of 3-series prostaglandins and 5-series leukotrienes which have low inflammatory bioactivity, and of E-series resolvins which have potent inflammation resolving capacities. 11, 12 By comparison, availability of the n-6 fatty acid LA and the n-3 fatty acid α-LNA was decreased. In addition, the findings suggest that quiescent mucosa is associated with higher AA and lower LA compared with control mucosa, which indicates that alteration of PUFA bioavailability occurs in the absence of significant infiltration of leukocytes, and despite no differences in dietary intake of fatty acids between these groups.
To our knowledge this is the first demonstration of comprehensive alterations in n-3 and n-6 PUFA availability associated with quiescent and active colonic mucosal inflammation in UC or other human inflammatory conditions. The findings are consistent in comparisons of inflamed with noninflamed colonic mucosa from the same patient and with external matched controls, and correlate proportionately to changes in the degree of histological and endoscopic inflammation. This is supported by the observation of no difference between non-inflamed colonic mucosa in UC patients and external controls.
Eicosanoid production is dependent on available nonesterified cytosolic PUFA, in turn released from esterified lipids by phospholipase A2. In the current study, comparisons have been made of n-6 and n-3 PUFA availability from both esterified and non-esterified pools, with consistent findings, which perhaps reflect the metabolic relationship between those pools.
Differences in PUFA content can arise due to differences in diet, in the rate of biosynthesis of AA from LA and of EPA from α-LNA, and in rate of utilisation, for example for eicosanoid synthesis. Lower measured intakes of essential fatty acids (LA and α-LNA) in patients with UC compared with age-sex matched controls is most likely due to dietary restrictions and altered dietary patterns used by patients to try to control the symptoms of their disease. However, differences between inflamed and non-inflamed tissue within the same individual cannot be due to differences in dietary intake. Higher levels of AA in inflamed mucosa in UC are unlikely to be explained through altered metabolism to produce eicosanoid metabolites including PGE 2 and LTB 4 , as these are known to be elevated in inflamed mucosa 6, 7 ; this would be likely to deplete AA.
Differences in PUFA composition are also unlikely to be due to leukocyte infiltration, as measured levels of PUFA within quiescent mucosa (with measured low/absent leukocyte content) demonstrate higher AA and lower LA than control mucosa, which is consistent with the changes seen in inflamed mucosa. In addition, although the fatty acid composition of infiltrating leukocytes differs from that of mucosal lipids, including elevated AA and lower LA, it is difficult to attribute the differences seen in all measured fatty acids to leukocyte infiltration; this is particularly relevant to the measured increase in DPA and DHA in inflamed tissue, as these are not characteristically high in leukocytes. 24 However, leukocyte infiltration may influence local eicosanoid production by drawing on a pool of bioavailable PUFA which have greater pro-inflammatory potential, and delivering these to mucosa.
The higher content of AA may therefore be due to induction of the pathway of its biosynthesis during the inflammatory response. This proposed up-regulation of the n-6 PUFA pathway from LA to AA is supported by the observed difference in the ratio of AA to its precursor LA between inflamed and noninflamed mucosa. Since the n-3 PUFA share the same pathway as the n-6 PUFA, upregulation of this pathway may also explain the increased ratio of EPA to its precursor α-LNA. However, the higher ratio of AA to EPA would suggest a differential enhancement of LA metabolism relative to that of α-LNA, which might be due to the much greater availability of LA than α-LNA.
Desaturase enzymes play a pivotal role in conversion of n-3 and n-6 PUFA from essential fatty acids to EPA and AA, and may be regulated by inflammatory cytokines or eicosanoids; however, little is known about this aspect of their regulation. This warrants further investigation. These findings have implications for our understanding of eicosanoid production in inflamed mucosa and its modification through altering substrate availability by dietary supplementation (e.g. with fish oils providing EPA). The observed increased availability of AA is consistent with the noted increased concentration of PGE 2 and LTB 4 and related pro-inflammatory mediators in inflamed mucosa. 6, 7 The markedly altered ratio of AA to EPA in both esterified and non-esterified lipids, compared to healthy subjects suggests that n-3 PUFA supplementation with fish oils may not bring about a significant rebalancing of n-3 vs. n-6 derived eicosanoids in UC, 25 even with the preferential utilisation of the former and despite the increased levels of n-3 PUFA seen within colonic mucosa in experimental studies of healthy volunteers and in patients. [26] [27] [28] [29] [30] [31] [32] [33] This may explain the failure of n-3 PUFA supplementation studies to achieve a significant effect on clinical outcomes, including relapse, in UC. 34, 35 The current findings suggest that inhibition of the synthetic pathway from LA to AA in combination with n-3 PUFA supplementation may rebalance the ratio of AA to EPA and modify eicosanoid profiles in favour of less inflammatory ones such as PGE 3 11 and LTB 5 , so producing immunomodulatory effect consistent with those seen in studies in healthy subjects. 36 Eicosanoid metabolites of AA, including LTB 4 , are potent neutrophil chemoattractants which appear elevated in inflamed mucosa in UC. Other eicosanoid species (e.g. PGD 2 ) may exert a protective effect on mucosa in quiescent UC. 37 PUFA bioavailability within quiescent mucosa appears fundamentally different to control mucosa with higher AA and reduced LA. This suggests that metabolic production of eicosanoid precursors is upregulated in quiescent mucosa and may explain elevation of eicosanoids derived from AA (e.g. PGD 2 ). Furthermore, it may explain how loss of intestinal eicosanoid homeostasis, as occurs with cyclooxygensase inhibition during non-steroidal anti-inflammatory drug use, is associated with an increased risk of UC relapse in quiescent mucosa. 38 This is supported by the known therapeutic effect of 5-ASA drugs, which exert therapeutic effect by binding to PPARγ receptors in the colonic epithelium with subsequent suppression of pro-inflammatory prostaglandin and leukotriene production. 7, 39, 40 Previous studies have demonstrated lower levels of EPA and DHA with higher levels of AA in mucosa of patients with UC. N-3 PUFA administration in the form of fish or seal oil was able to restore EPA and DHA levels, reduce AA levels, and impair eicosanoid production (PGE 2 and TXB 2 ) and was associated with improvements in patient symptoms. 7, 39, 40 In the current study we have used distal UC as a model of inflammation, in which a clear demarcation exists between inflamed and non-inflamed mucosa. Mucosal sampling of inflamed and non-inflamed tissue on either side of this demarcation enables scientific analysis, free from much of the confounding of inter-individual studies. Subgroup analysis of 18 patients receiving neither 5-ASA nor corticosteroids (each of which may influence eicosanoid production) demonstrates consistent alteration of PUFA bioavailability within the esterified pool, which confirms that the observed differences are not secondary to therapeutic effects. Comparison of non-inflamed mucosa in patients with distal UC to matched controls, does not demonstrate significant changes in PUFA, cytokines or eicosanoids (unpublished work).
In conclusion, we have demonstrated a higher content of the n-6 PUFA AA and a lower content of the n-3 PUFA EPA in inflamed colonic mucosa in UC. Along with corresponding changes in other fatty acids, and consistent changes in quiescent mucosa, we propose that the inflammation is associated with local alterations in the PUFA biosynthetic pathway. These novel findings suggest new targets for therapeutic manipulation with potential for combined n-3 PUFA supplementation and inhibition of the upregulated n-6 PUFA synthetic pathway. Further research is required in this area to determine the clinical response to altering mucosal PUFA availability on eicosanoid driven immunomodulation within inflamed tissue.
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